Xromi Pharmaceuticals

Nova Laboratories is a UK-based pharmaceutical company and contract development and manufacturing organization (CDMO) specializing in the development of complex drug products and orphan medicines. Founded in 1994 by former NHS pharmacy staff, the company is a leader in aseptic processing and has developed a proprietary pipeline of "Nova-branded" medicines, including Xromi (hydroxyurea oral solution) for sickle cell anemia and Xaluprine (mercaptopurine oral suspension) for acute lymphoblastic leukemia. Nova Laboratories is recognized for its expertise in stabilization technologies, such as its HydRIS and VitRIS platforms, which enable the storage of temperature-sensitive biologics and vaccines without refrigeration. The company operates globally, partnering with firms like Rare Disease Therapeutics in the US to bring its specialized pediatric and rare disease formulations to market.